A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older
Phase 3
Completed
- Conditions
- VaccineInfluenza
- Interventions
- Biological: ASP7374
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02366962
Study of ASP7374, Cell-culture-derived Influenza Vaccine
Phase 3
Completed
- Conditions
- InfluenzaVaccine
- Interventions
- Biological: ASP7374Biological: approved egg-derived TIV
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT01961947
A Study to Evaluate Intramuscular ASP7374
Phase 3
Completed
- Conditions
- VaccineInfluenza
- Interventions
- Biological: ASP7374
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01961960
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: ASP7374Biological: approved egg-derived TIV
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 1020
- Registration Number
- NCT01767896
A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Biological: ASP7373Biological: Placebo
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT01450579
A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- HealthyImmunogenicity of ASP7374
- Interventions
- Biological: ASP7374
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT01393951
Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults
Phase 2
Completed
- Conditions
- Influenza
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT01195038
- Locations
- 🇯🇵
UMN Investigational Site, Tokyo, Japan
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
Phase 2
Completed
- Conditions
- InfluenzaVirus Diseases
- Interventions
- Biological: UMN-0501
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- UMN Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00980447
- Locations
- 🇯🇵
National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan
🇯🇵National Hospital Organization Osaka Minami Medical Center, Kawachinagano City, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath